Healthscope in $550M deal to sell NZ pathology business
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out
more.
We are serious about journalism.
All subscriptions auto renew but are easy to cancel.
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Or use the information you’ve already given Google to create your subscription.
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.
On the Money: NZ's Don Johnson and more ...
Who did the PM crown as the "Don Johnson of New Zealand"?
The black market for oil will continue to thrive
Unless the West accepts higher prices, Russia and co will carry on evading sanctions.
Investing in US technology: Navigating a high-speed sector
A new exchange-traded fund gives Kiwis access to US tech giants.
Security of supply: Marsden Point isn’t the issue as assurance offered for liquid fuel supply
How NZ will stay fuelled despite major global supply risks.
